1. Scrip
  2. >>Therapy Areas
  3. >>Respiratory

Chiesi Returns To Respiratory Roots With Affibody Pact

Upfront And Milestone Payments up to $214m

 
• By Kevin Grogan

A busy start to the year sees the Italian firm adding to its respiratory portfolio by gaining access to the Swedish biotech’s investigational inhaled treatments.

Chiesi
• Source: Chiesi

Chiesi Farmaceutici S.p.A. is revisiting its respiratory heritage, teaming up with Sweden's Affibody AB to develop inhaled drugs in a deal that could be worth over $640m.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Respiratory

More from Therapy Areas